A Blinded, Four-Way Crossover in Healthy Subjects to Assess EEG After Administration of Ketamine, Placebo and AZD6765

Phase 1 Terminated 36 enrolled AstraZeneca

RandomizedCrossoverDouble-blindBasic science

Summary

This study will provide data to support preclinical to clinical translation by aligning preclinical and clinical efficacy assay with dose dependent changes in EEG.

Timeline

Start: 2010-05
Primary completion: 2011-01
Completion: 2011-01

Publications

Sanacora G, Smith MA, Pathak S, Su HL, Boeijinga PH, McCarthy DJ, Quirk MC. Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol Psychiatry. 2014 Sep;19(9):978-85. doi: 10.1038/mp.2013.130. Epub 2013 Oct 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Ketamine	Small molecule	0.5 mg/kg	—
Subject	lanicemine	Small molecule	75 mg	—
Subject	lanicemine	Small molecule	150 mg	—

Indications

No indication recorded.